KR940005286A - Tcf-ii를 유효성분으로 하는 의약 - Google Patents

Tcf-ii를 유효성분으로 하는 의약 Download PDF

Info

Publication number
KR940005286A
KR940005286A KR1019930013391A KR930013391A KR940005286A KR 940005286 A KR940005286 A KR 940005286A KR 1019930013391 A KR1019930013391 A KR 1019930013391A KR 930013391 A KR930013391 A KR 930013391A KR 940005286 A KR940005286 A KR 940005286A
Authority
KR
South Korea
Prior art keywords
tcf
treatment
formulation
wound
liver disease
Prior art date
Application number
KR1019930013391A
Other languages
English (en)
Other versions
KR100271087B1 (en
Inventor
히로아끼 마스나가
노부아끼 후지세
Original Assignee
가다야마 스미오
유끼지루시유교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP21222992A external-priority patent/JP3380573B2/ja
Priority claimed from JP21222792A external-priority patent/JP3619526B2/ja
Priority claimed from JP4234198A external-priority patent/JPH0656692A/ja
Application filed by 가다야마 스미오, 유끼지루시유교 가부시끼가이샤 filed Critical 가다야마 스미오
Publication of KR940005286A publication Critical patent/KR940005286A/ko
Application granted granted Critical
Publication of KR100271087B1 publication Critical patent/KR100271087B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

사람선유아세포유래의 당단백인 TCF-Ⅱ를 유효성분으로하는 의약.
특히 간장질환치료제, 단백합성촉진제 및 창상치료제.

Description

TCF-II를 유효성분으로 하는 의약
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 간장 절제 각종 병태 토끼에 대한 스롬포테스트 값을 나타내고,
제2도는 간장 절제 각종 병태 토끼의 혈청 피프리노겐량을 나타내고,
제3도는 간장 절제 각종 병태 토끼의 혈청 트리글리세리드량을 나타내고,
제4도는 간장 절제 각종 병태 토끼의 혈청 총단백량을 나타낸다.

Claims (13)

  1. TCF-Ⅱ를 유효성분으로하여 함유하는 간장질환치료제.
  2. 제1항에 있어서, 간장질환이 급성간염, 만성간엽, 간경변, 지방간 및 담즙을 혈형 간장해로 부터되는 군에서 선택되는 질환임을 특징으로하는 간장질환 치료제.
  3. 제1항에 있어서, 정제 TCF-Ⅱ를 성인 일인당 500∼300㎍, 1주간 수회 투여 될수 있는 제형으로 함을 특징으로 하는 간장질환 치료제.
  4. 제3항에 있어서, 제형이 주사제임을 특징으로 하는 간장질환 치료제.
  5. TCF-Ⅱ를 유효성분으로 함유하는 저단백혈증 치료용단백합성촉진제.
  6. 제5항에 있어서, 저단백혈증의 치료가 간장해성, 저단백혈증, 신부전에 의한 누출성 단백혈증 및 저영양성에 유래하는 저단백혈증으로 되는 군에서 선택되는 질환의 치료임을 특징으로 하는 저단백혈증치료용 단백합성 촉진제.
  7. 제6항에 있어서, 정제 TCF-Ⅱ를 성인 1인 1일당 500∼300㎍, 1주간수회투여 될수 있는 제형임을 특징으로 하는 저단백혈증치료용 단백합성 촉진제.
  8. 제7항에 있어서, 제형이 주사제임을 특징으로 하는 저단백혈증치료용 단백합성 촉진제.
  9. TCF-Ⅱ를 유효성분으로하는 창상치료제.
  10. 제9항에 있어서, 창상치료가 절상, 욕상, 수술창, 열창 및 외상성 피부 결손중으로되는 군에서 선택되는 창상의 치료임을 특징으로 하는 창상치료제.
  11. 제9항에 있어서, 정제 TCF-Ⅱ를 성인 1인 1일당 500∼300㎍, 1주간에 수회투여 될수 있는 제형임으로 특징으로 하는 창상치료제.
  12. 제11항에 있어서, 제형이 주사제임을 특징으로 하는 창상치료제.
  13. 제11항에 있어서, 제형이 도포형임을 특징으로 하는 창상치료제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930013391A 1992-07-16 1993-07-16 Protein synthesis stimulator comprising tcf-2 for the treatment of hypoproteinemia KR100271087B1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP92-212227 1992-07-16
JP92-212229 1992-07-16
JP21222992A JP3380573B2 (ja) 1992-07-16 1992-07-16 Ｔｃｆ−ｉｉを有効成分とする蛋白合成促進剤
JP21222792A JP3619526B2 (ja) 1992-07-16 1992-07-16 Ｔｃｆ−ｉｉを有効成分とする肝臓疾患治療剤
JP4234198A JPH0656692A (ja) 1992-08-10 1992-08-10 Ｔｃｆ−ｉｉを有効成分とする創傷治療剤
JP92-234198 1992-08-10

Publications (2)

Publication Number Publication Date
KR940005286A true KR940005286A (ko) 1994-03-21
KR100271087B1 KR100271087B1 (en) 2000-11-01

Family

ID=27329338

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930013391A KR100271087B1 (en) 1992-07-16 1993-07-16 Protein synthesis stimulator comprising tcf-2 for the treatment of hypoproteinemia

Country Status (7)

Country Link
EP (3) EP1719522B1 (ko)
KR (1) KR100271087B1 (ko)
AT (3) ATE428438T1 (ko)
CA (1) CA2100720C (ko)
DE (3) DE69334281D1 (ko)
DK (2) DK0588477T3 (ko)
ES (2) ES2276409T3 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714461A (en) * 1992-07-16 1998-02-03 Snow Brand Milk Products Co., Ltd. Medicinal compositions for the improvement of blood coagulation comprising TCF-II
JP3402476B2 (ja) * 1992-08-24 2003-05-06 生化学工業株式会社 リポ多糖結合性タンパク質及びその製造法
JP3680114B2 (ja) * 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
NZ298141A (en) * 1994-12-27 2000-12-22 Snow Brand Milk Products Co Ltd Treating lipid metabolism disorder using TCF-II
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
AU734766B2 (en) 1997-03-14 2001-06-21 Atlas Pharmaceuticals Inc. Agent for preventing and/or treating cachexia
JP3961064B2 (ja) * 1997-03-28 2007-08-15 第一製薬株式会社 腎疾患予防及び／又は治療剤
JPH1129493A (ja) * 1997-07-14 1999-02-02 Snow Brand Milk Prod Co Ltd 放射線障害予防及び／又は治療剤
JPH11269091A (ja) * 1998-03-19 1999-10-05 Snow Brand Milk Prod Co Ltd 敗血症予防及び／又は治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904753A (en) * 1970-02-20 1975-09-09 Research Corp Clinically active bovine growth hormone fraction
JPS58146293A (ja) 1982-02-26 1983-08-31 Mochida Pharmaceut Co Ltd 抗腫瘍性糖蛋白質の製造方法
US4708948A (en) 1984-04-20 1987-11-24 The United States Of America As Represented By The Department Of Health And Human Services Substantially purified tumor growth inhibitory factor
DE3419184A1 (de) 1984-05-23 1985-11-28 Dr.Ing.H.C. F. Porsche Ag, 7000 Stuttgart Zuendverteileranordnung an brennkraftmaschinen
JPS62103021A (ja) 1985-10-28 1987-05-13 Yoshitomi Pharmaceut Ind Ltd 細胞障害作用を有する生理活性物質およびその製造方法
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
JPS6410998A (en) 1986-12-22 1989-01-13 Green Cross Corp Tumor cell inhibitory factor
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
US5035887A (en) * 1989-09-07 1991-07-30 Institute Of Moelcular Biology, Inc. Wound healing composition of IL-1 and PDGF or IGF-1
EP0461560B1 (en) * 1990-06-11 1998-11-18 Toshikazu Nakamura Recombinant human hepatocyte growth factor and method for production thereof
DK0539590T3 (da) * 1990-07-13 1999-10-11 Snow Brand Milk Products Co Ltd Plasmid indeholdende DNA, som koder for aminosyresekvensen af TCF-II, en transformeret celle og fremstilling af et fysiolog

Also Published As

Publication number Publication date
DE69314586D1 (de) 1997-11-20
ES2276409T3 (es) 2007-06-16
KR100271087B1 (en) 2000-11-01
DE69334281D1 (de) 2009-05-28
EP0821969A2 (en) 1998-02-04
ATE428438T1 (de) 2009-05-15
CA2100720A1 (en) 1994-01-17
DE69314586T2 (de) 1998-02-19
ES2110057T3 (es) 1998-02-01
DE69334087T2 (de) 2007-07-05
AU673835B2 (en) 1996-11-28
ATE159171T1 (de) 1997-11-15
EP0588477A2 (en) 1994-03-23
DK0821969T3 (da) 2007-03-26
EP1719522A1 (en) 2006-11-08
AU4194593A (en) 1994-01-20
DE69334087D1 (de) 2007-01-04
EP0821969B1 (en) 2006-11-22
DK0588477T3 (da) 1998-03-30
EP0588477B1 (en) 1997-10-15
EP0588477A3 (en) 1994-05-25
ATE345809T1 (de) 2006-12-15
EP0821969A3 (en) 2000-12-13
EP1719522B1 (en) 2009-04-15
CA2100720C (en) 2003-03-11

Similar Documents

Publication Publication Date Title
US4871752A (en) Use of aryloxycarboxylic acid derivatives against dermatological diseases
Mindel et al. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes
US5116871A (en) Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis
Ehrlich et al. Inhibitory effects of vitamin E on collagen synthesis and wound repair.
DE59309635D1 (de) Topische Arzneiformen mit Insulin
EP0903148A3 (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
BRPI0011640B8 (pt) ácidos aldônicos de oligossacarídeo e seu uso tópico
DE69521693D1 (de) Taxanderivate enthaltende arzneizubereitungen
BRPI9908182B8 (pt) composições de proteína de matriz para cura de feridas
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
CY1110078T1 (el) Παρασκευασματα με ιωδιουχο ποβιδονη για την αγωγη τραυματων
KR940005286A (ko) Tcf-ii를 유효성분으로 하는 의약
KR970025615A (ko) 암 전이 억제제
KR960701648A (ko) Pdgf와 비타민 d를 함유하는 조골세포 성장 자극 조성물(oesteoblast growth stimulating compostion containing pdgf and vitamind)
BR9916860A (pt) Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1235153B (it) Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento
ATE80295T1 (de) Fettsaeure und cyclosporin enthaltende zusammensetzung mit ermaessigter nephrotoxizitaet.
KR910005858A (ko) 지방산 요법
KR920702225A (ko) 약학 조성물
Kocak et al. Treatment of external biliary, pancreatic and intestinal fistulas with a somatostatin analog
KR960705578A (ko) 경증 질환을 가진 b형 간염 보균자의 치료방법(method for treating hepatitis b carriers with minimal disease)
EP0080032A2 (en) Pharmaceutical preparation for treating herpetic lesions
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
US10292997B2 (en) Compositions and methods for stimulating wound healing

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090810

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee